Devices/Safety Alert·FDA MedWatch Safety Alerts

Dexcom Uncovers Theft of Scrapped Product, Notifies Potentially Impacted Users

MediumPublished May 29, 2026· AI-analyzed May 29, 2026View original FDA source
AI-generated regulatory interpretation. The four sections below are an analyst-style summary produced by an AI model from the original FDA source. Always verify against the source before any regulatory, clinical, or commercial decision.
What happened

Dexcom identified that specific lots of G7 sensors, which were designated as scrap and intended for destruction, were stolen. The company discovered the theft during routine quality and accounting reviews and has begun notifying potentially impacted users.

Who it affects

This alert affects users of the Dexcom G7 sensor, as well as regulatory, quality, and supply chain professionals at the manufacturer. The scope appears limited to the specific stolen lots.

Why it matters

The presence of stolen scrap product in the market poses significant safety risks, as these devices were previously earmarked for destruction due to non-conformance or other quality issues. This incident suggests a potential vulnerability in the product lifecycle management and disposal chain, necessitating a reconciliation between physical inventory and accounting records to detect unauthorized distribution.

Practical takeaway

Quality and accounting teams should review scrap disposal protocols and ensure chain of custody for products designated for destruction. Regulatory teams should monitor for unauthorized secondary market activity for these specific lots and ensure field safety notifications reach the intended users.

FDA source material

SAN DIEGO – MAY 26, 2026 – DexCom, Inc. (Nasdaq: DXCM), the global leader in glucose biosensing, announced today through ongoing quality and accounting reviews it recently identified certain lots of Dexcom G7 sensors originally designated as scrap and intended for destruction were stolen during the

Open in openFDA / FDA.gov
AI-generated interpretation. Always verify critical decisions against the original FDA source. Generated with google/gemini-3-flash-preview.